Policy

Thirty Australian women have already experienced restorative breast surgery using absorbable scaffolds designed to regenerate lost breast tissue, and the company behind the technology is moving quickly through human trials.

BCAL said the investment is a way to add an infectious disease diagnostics pillar to its existing early cancer detection business, linking Genetic Signatures EasyScreen PCR products and 3base technology with BCAL’s oncology liquid biopsy and breast cancer test offerings.

AdAlta has announced a strategic collaboration with Oktopi to access its software-as-a-service knowledge system, designed to sharpen decisions in medicine development.

OncoSil Medical has been chosen to join PALACROS, a major European academic consortium aimed at improving outcomes for patients with unresectable locally advanced pancreatic cancer.

Starpharma has reported encouraging preclinical results for its DEP HER2-targeted radiotherapy candidate, DEP HER2 Lu, paving the way for a planned first-in-human Phase 1 study in the second half of 2026.

Cartherics has been recognised as the Emerging Leader in Allogeneic Cell Therapy at the Asia Pacific Cell and Gene Therapy Excellence Awards 2026, a milestone that highlights the company's rise in the off-the-shelf immune cell therapy field.

Algorae Pharmaceuticals has been announced as a founding participant and the healthcare and life sciences launch partner for the Sovereign AI Infrastructure initiative, led by AgenticScale.ai and built on NVIDIA-accelerated technology.

Chief Executive Officer James Graham said, "The capital raising comes at an exciting time for the Recce business, having recently signed a non-binding term sheet with a leading Middle Eastern Pharmaceuticals Company, and ahead of interim data readouts in Indonesia, which is a positive step towards the potential commercialisation of R327G."

Dr Bill Mezzanotte, CSL’s Head of Research and Development, said, “While we are disappointed in the outcome of the Article 20 procedure, we will respect the regulatory process and are committed to implementing it in full."

The company said the funds will underwrite ongoing investment in the development and commercialisation of its blood-based early cancer detection portfolio and support planned activities through 2027.

Neuren CEO Jon Pilcher said, “I am so delighted for all stakeholders to see this positive outcome from the CHMP re-examination process recommending marketing authorisation for DAYBU in the EU."

INOVIQ says the findings reinforce the broader potential of its off-the-shelf cell-free CAR exosome platform, which has now shown activity in triple-negative breast cancer, non-small cell lung cancer, and ovarian cancer.